Drugs / Ertafolide
Ertafolide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00507741 | Aug 2007 → Apr 2009 | endometrial cancer, ovarian cancer | Endocyte | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ertafolide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00507741 ↗ |
| Known as | EC20 | “All participants will undergo imaging with the FR targeting investigational imaging agent ertafolide (EC20, FolateScan) during the screening period to confirm eligibility for...” NCT00507741 ↗ |
| Known as | FolateScan | “All participants will undergo imaging with the FR targeting investigational imaging agent ertafolide (EC20, FolateScan) during the screening period to confirm eligibility for...” NCT00507741 ↗ |
| Modality | Diagnostic / imaging agent | “investigational imaging agent ertafolide (EC20, FolateScan)” NCT00507741 ↗ |